The Centers for Medicare & Medicaid Services published final negotiated prices under the Inflation Reduction Act for the second round of medications, including GLP‑1 weight‑loss drugs Ozempic and Wegovy. The rule details government‑negotiated price adjustments intended to lower Medicare drug spending starting with specified launch years. The move intensifies commercial and policy pressures on manufacturers of high‑cost therapies and will influence negotiations, pricing strategies and payer access decisions across the industry as companies and health systems model the financial impacts of the IRA framework.